Sales & Marketing News | pharmaphorum

News

Vanda slams FDA rejection of gastroparesis drug

The FDA has declined to approve Vanda Pharma's tradipitant for delayed gastric emptying (gastroparesis), prompting a furious response from the company.

News

ICER mulls GSK COPD drugs ahead of next Medicare negotiation

The list for the next round of medicines that will be subject to Medicare price negotiations isn’t in yet, but the Institute for Clinical and Economic Review (ICER) reckons a chronic obstru

News

Organon makes dermatology play with $1.2bn Dermavant buyout

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, which is also under review by the FDA for atopic dermatitis.

News

PBM strikes back at FTC over drug pricing report

A pharmacy benefit manager has thrown a legal punch at the Federal Trade Commission (FTC), taking issue with the agency's recent report accusing PBMs of using anti-competitive practices to

News

Noom offers cut-price compounded GLP-1 drug for obesity

Digital health company Noom has launched a compound pharmacy-made version of Novo Nordisk's obesity drug semaglutide to make the drug more accessible to consumers in the US.

News

Lilly on alert as new Kisqali approval threatens Verzenio

Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly.

Vanda slams FDA rejection of gastroparesis drug

ICER mulls GSK COPD drugs ahead of next Medicare negotiation

Organon makes dermatology play with $1.2bn Dermavant buyout

PBM strikes back at FTC over drug pricing report

Noom offers cut-price compounded GLP-1 drug for obesity

Lilly on alert as new Kisqali approval threatens Verzenio

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks